FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including ...
The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...
Miist Therapeutics, a physics-based developer of inhaled medicines, today announced $7M in seed funding from investors ...
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability ...
With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...
Pharmaceutical Technology on MSN1d
Novartis signs agreement to acquire Anthos for $925m upfrontNovartis has agreed to acquire Anthos Therapeutics, a Boston-based clinical-stage biopharmaceutical company, for an upfront ...
Sirnaomics is poised to improve outcomes in therapeutic areas such as oncology and fibrosis with a pipeline of prospects built on proprietary delivery technology platforms able to deliver siRNAs ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback